NASDAQ · GUTS
Healthcare · Biotechnology
$4.41
Down-$0.39 (-8.73%)
Updated Oct 13, 2026, 9:20 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GUTS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
GUTS closed at $4.41 after 21 trading sessions, up 621.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $4.41 | $4.5799 | $4.3463 | $4.41 | 134.62K |
| Oct 9, 2026 | $4.21 | $4.55 | $4.20 | $4.42 | 198.3K |
| Oct 8, 2026 | $4.50 | $4.5299 | $4.1401 | $4.23 | 300.54K |
| Oct 7, 2026 | $4.53 | $4.73 | $4.431 | $4.52 | 104.5K |
| Oct 6, 2026 | $4.56 | $4.75 | $4.40 | $4.57 | 156.72K |
| Oct 5, 2026 | $4.80 | $4.8145 | $4.33 | $4.56 | 291.22K |
| Oct 2, 2026 | $5.3748 | $5.3946 | $4.80 | $4.8792 | 254.82K |
| Oct 1, 2026 | $6.0048 | $6.1704 | $5.1036 | $5.4012 | 462.33K |
| Sep 30, 2026 | $6.48 | $6.9912 | $6.12 | $6.5328 | 179.48K |
| Sep 29, 2026 | $5.6328 | $6.2664 | $5.544 | $6.24 | 139.71K |
| Sep 28, 2026 | $0.484 | $0.484 | $0.4545 | $0.471 | 1.4M |
| Sep 25, 2026 | $0.485 | $0.4989 | $0.445 | $0.4856 | 3.26M |
| Sep 24, 2026 | $0.472 | $0.4856 | $0.4502 | $0.4699 | 1.55M |
| Sep 23, 2026 | $0.5516 | $0.5587 | $0.4556 | $0.4856 | 4.73M |
| Sep 22, 2026 | $0.58 | $0.5998 | $0.5473 | $0.553 | 1.12M |
| Sep 21, 2026 | $0.63 | $0.63 | $0.5708 | $0.5717 | 685.3K |
| Sep 18, 2026 | $0.598 | $0.60 | $0.586 | $0.60 | 1.82M |
| Sep 17, 2026 | $0.567 | $0.60 | $0.567 | $0.5908 | 752.92K |
| Sep 16, 2026 | $0.563 | $0.62 | $0.555 | $0.5625 | 860.73K |
| Sep 15, 2026 | $0.60 | $0.614 | $0.56 | $0.565 | 1.74M |
| Sep 14, 2026 | $0.6311 | $0.65 | $0.585 | $0.6116 | 1.96M |
The latest Smart Investors Daily articles mentioning GUTS.
Company
Market Activity
Research & News
GUTS research
Company profile and research snapshot.
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2026 | Craig-Hallum | Buy | — |
| Jun 4, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 24, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 26, 2026 | Canaccord Genuity | Buy | — |
| Jan 30, 2026 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
Fractyl Health, Inc. (GUTS) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 5:35 PM EDTCompany ParticipantsHarith Rajagopalan -...
Yahoo · Sep 9, 2026
BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment ConferenceFormat: On-demand
Yahoo · Sep 1, 2026
Fractyl Health (NASDAQ:GUTS) outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines. The company said Revita is designed for post-GLP-
SeekingAlpha · Sep 1, 2026
Fractyl Health, Inc. (GUTS) Discusses Commercialization Strategy for Investigational Post-GLP-1 Procedural Therapy September 1, 2026 11:00 AM EDTCompany...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GUTS.
